Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Covert

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Ophthalmology|May 10, 2005
Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?Alan L Robin, David Covert
Current Medical Research and Opinion|May 20, 2006
Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprostDavid Covert, Alan L Robin
Clinical Ophthalmology (Auckland, N.Z.)|August 12, 2009
Travoprost in the management of open-angle glaucoma and ocular hypertensionPhilippe Denis, David Covert, Anthony Realini
Ophthalmology|October 4, 2005
Systemic medications and glaucoma patientsDavid Covert, Alan L Robin, Gary D Novack
Ophthalmic Epidemiology|April 4, 2006
Validation of the Daily Living Tasks Dependent on Vision (DLTV) questionnaire in a U.S. population with age-related macular degenerationJordana K Schmier, Michael T Halpern, David Covert
Journal of Pharmacokinetics and Pharmacodynamics|April 23, 2018
Projected 24-hour post-dose ocular itching scores post-treatment with olopatadine 0.7% versus 0.2Matthew L Fidler, Abayomi Ogundele, David Covert, et al.
Survey of Ophthalmology|January 24, 2007
Quality of life and health economic assessments of age-related macular degenerationDavid Covert, Gilles Berdeaux, Jan Mitchell, et al.
Health Care Financing Review|February 13, 2007
Resource utilization and costs of age-related macular degenerationMichael T Halpern, Jordana K Schmier, David Covert, et al.
Retina (Philadelphia, Pa.)|December 8, 2006
Impact of visual impairment on use of caregiving by individuals with age-related macular degenerationJordana K Schmier, Michael T Halpern, David Covert, et al.
Journal of Medical Economics|May 20, 2009
Cost comparison of prostaglandin analogues: a Canadian population-based analysisMichael Iskedjian, John H Walker, Olivier Desjardins, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Ophthalmology|May 10, 2005
Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?Alan L Robin, David Covert
Current Medical Research and Opinion|May 20, 2006
Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprostDavid Covert, Alan L Robin
Clinical Ophthalmology (Auckland, N.Z.)|August 12, 2009
Travoprost in the management of open-angle glaucoma and ocular hypertensionPhilippe Denis, David Covert, Anthony Realini
Ophthalmology|October 4, 2005
Systemic medications and glaucoma patientsDavid Covert, Alan L Robin, Gary D Novack
Ophthalmic Epidemiology|April 4, 2006
Validation of the Daily Living Tasks Dependent on Vision (DLTV) questionnaire in a U.S. population with age-related macular degenerationJordana K Schmier, Michael T Halpern, David Covert
Journal of Pharmacokinetics and Pharmacodynamics|April 23, 2018
Projected 24-hour post-dose ocular itching scores post-treatment with olopatadine 0.7% versus 0.2Matthew L Fidler, Abayomi Ogundele, David Covert, et al.
Survey of Ophthalmology|January 24, 2007
Quality of life and health economic assessments of age-related macular degenerationDavid Covert, Gilles Berdeaux, Jan Mitchell, et al.
Health Care Financing Review|February 13, 2007
Resource utilization and costs of age-related macular degenerationMichael T Halpern, Jordana K Schmier, David Covert, et al.
Retina (Philadelphia, Pa.)|December 8, 2006
Impact of visual impairment on use of caregiving by individuals with age-related macular degenerationJordana K Schmier, Michael T Halpern, David Covert, et al.
Journal of Medical Economics|May 20, 2009
Cost comparison of prostaglandin analogues: a Canadian population-based analysisMichael Iskedjian, John H Walker, Olivier Desjardins, et al.
Pageof 3